ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · Real-Time Price · USD
81.97
-0.32 (-0.39%)
May 22, 2026, 4:00 PM EDT - Market closed
Assets$70.63M
Expense Ratio0.95%
PE Ration/a
Shares Out870,000
Dividend (ttm)$0.49
Dividend Yield0.60%
Ex-Dividend DateMar 25, 2026
Payout FrequencyQuarterly
Payout Ration/a
Volume6,034
Open83.13
Previous Close82.29
Day's Range81.82 - 83.21
52-Week Low42.09
52-Week High90.91
Beta1.25
Holdings263
Inception DateApr 8, 2010

About BIB

Fund Home Page

The ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.

Asset Class Equity
Category Trading--Leveraged Equity
Stock Exchange NASDAQ
Ticker Symbol BIB
ETF Provider ProShares
Index Tracked NASDAQ / Biotechnology

Top 10 Holdings

153.46% of assets
NameSymbolWeight
NASDAQ BIO INDEX SWAP BNP PARIBASn/a31.55%
NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAn/a29.05%
NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAn/a27.81%
NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALn/a21.75%
NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEn/a20.71%
NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGn/a5.22%
Gilead Sciences, Inc.GILD4.66%
Vertex Pharmaceuticals IncorporatedVRTX4.64%
Amgen Inc.AMGN4.62%
Regeneron Pharmaceuticals, Inc.REGN3.45%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Mar 25, 2026$0.00714Mar 31, 2026
Dec 24, 2025$0.13464Dec 31, 2025
Sep 24, 2025$0.18054Sep 30, 2025
Jun 25, 2025$0.17058Jul 1, 2025
Mar 26, 2025$0.13094Apr 1, 2025
Dec 23, 2024$0.39644Dec 31, 2024
Full Dividend History

Performance

BIB had a total return of 90.57% in the past year, including dividends. Since the fund's inception, the average annual return has been 16.31%.

News

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

Biotech ETFs are regaining attention as analyst targets signal renewed upside heading into 2026, particularly among small- and mid-cap drug developers. The ProShares Ultra Nasdaq Biotechnology ETF ($B...

3 months ago - TipRanks